rationale for combining olaparib with neratinib in her2 uterine serous carcinoma
Published 5 years ago • 80 plays • Length 1:52Download video MP4
Download video MP3
Similar videos
-
1:19
explaining synergy in the olaparib/neratinib combination for uterine serous carcinomas
-
1:45
dr. yadav on the olaparib/neratinib combo in her2 uterine serous carcinoma
-
2:03
dr. yadav on olaparib/neratinib in her2-overexpressing uterine serous carcinoma
-
1:06
dr. santin on rationale for trastuzumab in uterine serous carcinoma
-
2:48
rationale for olaparib in advanced ovarian cancer
-
5:37
r/r her2 metastatic breast cancer: neratinib ae management
-
1:01
key takeaways for neratinib plus t-dm1 combination in breast cancer
-
1:24
dr. yadav on synergy of novel combination in uterine serous carcinoma
-
1:14
dr. lin on cns-specific outcomes with neratinib in her2 breast cancer
-
1:37
dr. traina on conversations on extended adjuvant therapy with neratinib in her2 breast cancer
-
1:27
dr. fader on trastuzumab/chemo in her2 uterine serous carcinoma
-
1:57
dr. dietrich on adverse event management for neratinib in breast cancer
-
20:43
updates in advanced & recurrent endometrial cancer: molecular classification & emerging therapies
-
1:23
dr. liu on phase 2 study results of adavosertib in recurrent uterine serous carcinoma
-
6:32
case 1: use of niraparib in ovarian cancer
-
1:07
dr. mitri on neratinib and pertuzumab in her2-amplified breast cancer
-
1:13
addressing the role of parp inhibitors in different breast cancer settings
-
1:14:46
uterine/endometrial cancer 201: what you need to know